CenterBook Partners LP Purchases New Position in The Clorox Company (NYSE:CLX)

CenterBook Partners LP acquired a new position in shares of The Clorox Company (NYSE:CLX - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 13,236 shares of the company's stock, valued at approximately $1,949,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Redwood Park Advisors LLC purchased a new stake in shares of Clorox in the fourth quarter worth $26,000. Millstone Evans Group LLC bought a new position in shares of Clorox during the 4th quarter worth approximately $31,000. Wood Tarver Financial Group LLC acquired a new position in Clorox during the 4th quarter valued at approximately $31,000. GKV Capital Management Co. Inc. acquired a new stake in shares of Clorox in the fourth quarter worth $32,000. Finally, Aster Capital Management DIFC Ltd purchased a new stake in Clorox during the fourth quarter worth $33,000. Institutional investors own 78.53% of the company's stock.

Wall Street Analysts Forecast Growth

CLX has been the subject of several recent analyst reports. Barclays set a $119.00 price objective on shares of Clorox and gave the stock an "underweight" rating in a research report on Tuesday. Jefferies Financial Group dropped their price objective on shares of Clorox from $167.00 to $145.00 and set a "buy" rating on the stock in a research note on Thursday, June 26th. JPMorgan Chase & Co. lowered their target price on shares of Clorox from $151.00 to $144.00 and set a "neutral" rating on the stock in a research report on Tuesday, May 6th. Morgan Stanley dropped their price objective on shares of Clorox from $165.00 to $150.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. Finally, Citigroup reaffirmed a "neutral" rating and set a $135.00 price target (down previously from $140.00) on shares of Clorox in a research note on Tuesday. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and one has given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $146.83.

Clorox Stock Performance

Shares of NYSE CLX traded up $2.71 during mid-day trading on Wednesday, reaching $126.88. 1,567,620 shares of the company's stock were exchanged, compared to its average volume of 1,420,579. The Clorox Company has a 52 week low of $117.35 and a 52 week high of $171.37. The firm has a 50-day moving average price of $127.84 and a two-hundred day moving average price of $141.91. The firm has a market capitalization of $15.64 billion, a price-to-earnings ratio of 22.78, a price-to-earnings-growth ratio of 3.06 and a beta of 0.51. The company has a debt-to-equity ratio of 13.07, a current ratio of 0.74 and a quick ratio of 0.44.

Clorox (NYSE:CLX - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported $1.45 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.12). Clorox had a return on equity of 324.23% and a net margin of 9.89%. The business had revenue of $1.67 billion for the quarter, compared to analysts' expectations of $1.74 billion. During the same period in the previous year, the firm posted $1.71 EPS. The firm's revenue for the quarter was down 8.0% compared to the same quarter last year. Analysts predict that The Clorox Company will post 7.15 EPS for the current year.

Insider Activity at Clorox

In other news, Director Pierre R. Breber bought 4,000 shares of the company's stock in a transaction on Wednesday, May 7th. The shares were acquired at an average cost of $136.57 per share, with a total value of $546,280.00. Following the completion of the transaction, the director owned 4,000 shares of the company's stock, valued at approximately $546,280. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.57% of the stock is owned by company insiders.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.